CytomX Therapeutics (CTMX) EBT (2016 - 2025)
Historic EBT for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' EBT fell 34445.4% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 8766.93%. This contributed to the annual value of $32.1 million for FY2024, which is 86578.39% up from last year.
- According to the latest figures from Q3 2025, CytomX Therapeutics' EBT is -$14.2 million, which was down 34445.4% from -$91000.0 recorded in Q2 2025.
- CytomX Therapeutics' EBT's 5-year high stood at $23.6 million during Q1 2025, with a 5-year trough of -$34.8 million in Q4 2021.
- Moreover, its 5-year median value for EBT was -$6.5 million (2024), whereas its average is -$9.0 million.
- Examining YoY changes over the last 5 years, CytomX Therapeutics' EBT showed a top increase of 89359.92% in 2024 and a maximum decrease of 49641.21% in 2024.
- CytomX Therapeutics' EBT (Quarter) stood at -$34.8 million in 2021, then soared by 74.8% to -$8.8 million in 2022, then surged by 121.72% to $1.9 million in 2023, then surged by 893.6% to $18.9 million in 2024, then tumbled by 174.83% to -$14.2 million in 2025.
- Its EBT stands at -$14.2 million for Q3 2025, versus -$91000.0 for Q2 2025 and $23.6 million for Q1 2025.